

Diego Muñoz-Torrero

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/6291145/publications.pdf>

Version: 2024-02-01

122
papers

3,507
citations

126901
33
h-index

155644
55
g-index

130
all docs

130
docs citations

130
times ranked

3763
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 4909-4925.	6.4	22
2	Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis. <i>Pharmaceuticals</i> , 2022, 15, 545.	3.8	21
3	The Cream of the Crop of the Medicinal Chemistry Section of Molecules 2019. <i>Molecules</i> , 2021, 26, 1053.	3.8	0
4	Clock/Sleep-Dependent Learning and Memory in Male 3xTg-AD Mice at Advanced Disease Stages and Extrinsic Effects of Huprine X and the Novel Multitarget Agent AVCRI104P3. <i>Brain Sciences</i> , 2021, 11, 426.	2.3	2
5	Protective Role of a Donepezil-Huprine Hybrid against the A β 2-Amyloid (1-42) Effect on Human Erythrocytes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9563.	4.1	8
6	From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects. <i>European Journal of Medicinal Chemistry</i> , 2021, 225, 113779.	5.5	7
7	Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 812-839.	6.4	45
8	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes 6. <i>Molecules</i> , 2020, 25, 119.	3.8	8
9	Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 9360-9390.	6.4	25
10	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes 7. <i>Molecules</i> , 2020, 25, 2968.	3.8	5
11	We've Come a Long Way, Baby: Announcing a Special Issue to Commemorate the Publication of Molecules' 20,000th Paper. <i>Molecules</i> , 2020, 25, 173.	3.8	0
12	Evaluation of the effects of acetylcholinesterase inhibitors in the zebrafish touch-evoked response: quantitative vs. qualitative assessment. <i>Environmental Sciences Europe</i> , 2020, 32, .	5.5	7
13	A novel class of multitarget anti-Alzheimer benzohomoadamantane-chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. <i>European Journal of Medicinal Chemistry</i> , 2019, 180, 613-626.	5.5	26
14	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes 5. <i>Molecules</i> , 2019, 24, 2415.	3.8	5
15	Synthesis, In Vitro Profiling, and In Vivo Efficacy Studies of a New Family of Multitarget Anti-Alzheimer Compounds. <i>Proceedings (mdpi)</i> , 2019, 22, .	0.2	0
16	Multicomponent reactions: A mighty journey partner for infectious tropical disease drug discovery. <i>Annual Reports in Medicinal Chemistry</i> , 2019, , 181-217.	0.9	3
17	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes 4. <i>Molecules</i> , 2019, 24, 130.	3.8	4
18	Amyloid Pan-inhibitors: One Family of Compounds To Cope with All Conformational Diseases. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1311-1317.	3.5	14

#	ARTICLE	IF	CITATIONS
19	Bacterial Inclusion Bodies for Anti-Amyloid Drug Discovery: Current and Future Screening Methods. Current Protein and Peptide Science, 2019, 20, 563-576.	1.4	7
20	First homology model of Plasmodium falciparum glucose-6-phosphate dehydrogenase: Discovery of selective substrate analog-based inhibitors as novel antimalarial agents. European Journal of Medicinal Chemistry, 2018, 146, 108-122.	5.5	9
21	Huprine X Attenuates The Neurotoxicity Induced by Kainic Acid, Especially Brain Inflammation. Basic and Clinical Pharmacology and Toxicology, 2018, 122, 94-103.	2.5	2
22	Neuroprotective Effects of the Multitarget Agent AVCRI104P3 in Brain of Middle-Aged Mice. International Journal of Molecular Sciences, 2018, 19, 2615.	4.1	3
23	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3. Molecules, 2018, 23, 1596.	3.8	1
24	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-2. Molecules, 2018, 23, 65.	3.8	2
25	Tetrasubstituted Imidazolium Salts as Potent Antiparasitic Agents against African and American Trypanosomiasis. Molecules, 2018, 23, 177.	3.8	5
26	Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis. Molecules, 2018, 23, 634.	3.8	28
27	Synthesis and Biological Evaluation of Heteroarylnonanenitriles as Potential Antitrypanosomal Agents: Serendipitous Discovery of Novel Anticholinesterase Hits. Letters in Organic Chemistry, 2018, 15, 455-461.	0.5	0
28	Combined in Vitro Cell-Based/in Silico Screening of Naturally Occurring Flavonoids and Phenolic Compounds as Potential Anti-Alzheimer Drugs. Journal of Natural Products, 2017, 80, 278-289.	3.0	68
29	Behavioural effects of novel multitarget anticholinesterase derivatives in Alzheimer's disease. Behavioural Pharmacology, 2017, 28, 124-131.	1.7	8
30	Design, synthesis and multitarget biological profiling of second-generation anti-Alzheimer rhinopneumonin huprine hybrids. Future Medicinal Chemistry, 2017, 9, 965-981.	2.3	40
31	Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes. Molecules, 2017, 22, 743.	3.8	3
32	Design of Potential Antimalarial Agents Based on a Homology Model of Plasmodium falciparum Glucose-6-Phosphate Dehydrogenase. Proceedings (mdpi), 2017, 1, 665.	0.2	0
33	Introduction to the 1st Molecules Medicinal Chemistry Symposium (MMCS), Barcelona, 8 September 2017. Proceedings (mdpi), 2017, 1, .	0.2	0
34	Reaction of 3-Amino-1,2,4-Triazole with Diethyl Phosphite and Triethyl Orthoformate: Acid-Base Properties and Antiosteoporotic Activities of the Products. Molecules, 2017, 22, 254.	3.8	6
35	Multitarget Anti-Alzheimer Hybrid Compounds. , 2017, , 167-192.		9
36	Pyrrole and Fused Pyrrole Compounds with Bioactivity against Inflammatory Mediators. Molecules, 2017, 22, 461.	3.8	37

#	ARTICLE	IF	CITATIONS
37	Unveiling a novel transient druggable pocket in BACE-1 through molecular simulations: Conformational analysis and binding mode of multisite inhibitors. <i>PLoS ONE</i> , 2017, 12, e0177683.	2.5	17
38	Insertion of Isocyanides into Nâ”Si Bonds: Multicomponent Reactions with Azines Leading to Potent Antiparasitic Compounds. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 8994-8998.	13.8	28
39	Insertion of Isocyanides into Nâ”Si Bonds: Multicomponent Reactions with Azines Leading to Potent Antiparasitic Compounds. <i>Angewandte Chemie</i> , 2016, 128, 9140-9144.	2.0	7
40	Synthesis and biological evaluation of N -cyanoalkyl-, N -aminoalkyl-, and N -guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 5162-5171.	3.0	9
41	Ultra rapid in vivo screening for anti-Alzheimer anti-amyloid drugs. <i>Scientific Reports</i> , 2016, 6, 23349.	3.3	37
42	Design, synthesis and biological evaluation of N-methyl-N-[(1,2,3-triazol-4-yl)alkyl]propargylamines as novel monoamine oxidase B inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 4835-4854.	3.0	23
43	A fast and specific method to screen for intracellular amyloid inhibitors using bacterial model systems. <i>European Journal of Medicinal Chemistry</i> , 2016, 121, 785-792.	5.5	9
44	Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in A β PPswe/PS-1 Mice of Different Ages. <i>Current Alzheimer Research</i> , 2016, 13, 1017-1029.	1.4	14
45	AVCRI104P3, a novel multitarget compound with cognition-enhancing and anxiolytic activities: Studies in cognitively poor middle-aged mice. <i>Behavioural Brain Research</i> , 2015, 286, 97-103.	2.2	9
46	Synthesis, biological profiling and mechanistic studies of 4-aminoquinoline-based heterodimeric compounds with dual trypanocidalâ”antiplasmodial activity. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5156-5167.	3.0	14
47	Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6018-6032.	6.4	58
48	Multigram Synthesis and in Vivo Efficacy Studies of a Novel Multitarget Anti-Alzheimerâ”™s Compound. <i>Molecules</i> , 2015, 20, 4492-4515.	3.8	17
49	Interaction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases. <i>Acta Neuropathologica Communications</i> , 2015, 3, 18.	5.2	12
50	Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity. <i>European Journal of Medicinal Chemistry</i> , 2015, 105, 120-137.	5.5	52
51	1,2,3,4-Tetrahydrobenzo[h][1,6]naphthyridines as a new family of potent peripheral-to-midgorge-site inhibitors of acetylcholinesterase: Synthesis, pharmacological evaluation and mechanistic studies. <i>European Journal of Medicinal Chemistry</i> , 2014, 73, 141-152.	5.5	39
52	Synthesis and antiprotozoal activity of oligomethylene- and p-phenylene-bis(methylene)-linked bis(+)-huprines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5435-5438.	2.2	9
53	Shogaolâ”huprine hybrids: Dual antioxidant and anticholinesterase agents with β -amyloid and tau anti-aggregating properties. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 5298-5307.	3.0	37
54	Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β -amyloid, tau, and cholinesterase pathologies. <i>European Journal of Medicinal Chemistry</i> , 2014, 84, 107-117.	5.5	57

#	ARTICLE	IF	CITATIONS
55	Synthesis and Multitarget Biological Profiling of a Novel Family of Rhein Derivatives As Disease-Modifying Anti-Alzheimer Agents. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2549-2567.	6.4	132
56	Thioflavin-S Staining of Bacterial Inclusion Bodies for the Fast, Simple, and Inexpensive Screening of Amyloid Aggregation Inhibitors. <i>Current Medicinal Chemistry</i> , 2014, 21, 1152-1159.	2.4	44
57	Huprine X and Huperzine A Improve Cognition and Regulate Some Neurochemical Processes Related with Alzheimer's Disease in Triple Transgenic Mice (3xTg-AD). <i>Neurodegenerative Diseases</i> , 2013, 11, 129-140.	1.4	38
58	Editorial (Hot Topic: Complexity against Complexity: Multitarget Drugs). <i>Current Medicinal Chemistry</i> , 2013, 20, 1621-1622.	2.4	7
59	Undifferentiated and Differentiated PC12 Cells Protected by Huprines Against Injury Induced by Hydrogen Peroxide. <i>PLoS ONE</i> , 2013, 8, e74344.	2.5	17
60	Human Disease and Drug Pharmacology, Complex as Real Life. <i>Current Medicinal Chemistry</i> , 2013, 20, 1623-1634.	2.4	33
61	Dual Inhibitors of β -Amyloid Aggregation and Acetylcholinesterase as Multi-Target Anti-Alzheimer Drug Candidates. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 1820-1842.	2.1	69
62	Expanding the Multipotent Profile of Huprine-Tacrine Heterodimers as Disease-Modifying Anti-Alzheimer Agents. <i>Neurodegenerative Diseases</i> , 2012, 10, 96-99.	1.4	7
63	Huprine-Tacrine Heterodimers as Anti-Amyloidogenic Compounds of Potential Interest against Alzheimer's and Prion Diseases. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 661-669.	6.4	90
64	Diastereoselective preparation of (S)-(1,4,4-trimethylpyrrolidin-3-yl)amine, a new chiral 1,2-diamine for thiourea-type organocatalysts. <i>Tetrahedron: Asymmetry</i> , 2011, 22, 745-751.	1.8	6
65	Huprines as a new family of dual acting trypanocidal antiplasmodial agents. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1702-1707.	3.0	9
66	Behavioural effects and regulation of PKC δ and MAPK by huprine X in middle aged mice. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 95, 485-493.	2.9	20
67	Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates. <i>Chemico-Biological Interactions</i> , 2010, 187, 411-415.	4.0	71
68	Novel Huprine Derivatives with Inhibitory Activity toward β -Amyloid Aggregation and Formation as Disease-Modifying Anti-Alzheimer Drug Candidates. <i>ChemMedChem</i> , 2010, 5, 1855-1870.	3.2	56
69	Straightforward preparation of enantiopure 3-amino-4,4-dimethylpyrrolidin-2-one and its derivatives. <i>Tetrahedron: Asymmetry</i> , 2010, 21, 2124-2135.	1.8	4
70	Structural Determinants of the Multifunctional Profile of Dual Binding Site Acetylcholinesterase Inhibitors as Anti-Alzheimer Agents. <i>Current Pharmaceutical Design</i> , 2010, 16, 2818-2836.	1.9	51
71	Effect of Huprine X on β -Amyloid, Synaptophysin and $\alpha 7$ Neuronal Nicotinic Acetylcholine Receptors in the Brain of 3xTg-AD and APP ^{swe} Transgenic Mice. <i>Neurodegenerative Diseases</i> , 2010, 7, 379-388.	1.4	31
72	Evaluation of Cryptolepine and Huperzine Derivatives as Lead Compounds towards New Agents for the Treatment of Human African Trypanosomiasis. <i>Natural Product Communications</i> , 2009, 4, 1934578X0900400.	0.5	8

#	ARTICLE	IF	CITATIONS
73	Pyrano[3,2- <i>c</i>]quinoline-6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β -Amyloid-Directed Anti-Alzheimer Compounds. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 5365-5379.	6.4	164
74	Editorial: Hot Topic: [Exploiting Multivalency in Drug Design (Executive Editor: Diego Munoz-Torrero)]. <i>Current Pharmaceutical Design</i> , 2009, 15, 585-586.	1.9	4
75	Novel Donepezil-Based Inhibitors of Acetyl- and Butyrylcholinesterase and Acetylcholinesterase-Induced β -Amyloid Aggregation. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 3588-3598.	6.4	186
76	Huprines for Alzheimer's disease drug development. <i>Expert Opinion on Drug Discovery</i> , 2008, 3, 65-81.	5.0	19
77	Synthesis and Absolute Configuration of Novel <i>N</i> - <i>O</i> -Psiconucleosides Using (<i>R</i>)- <i>N</i> -Phenylpantolactam as a Resolution Agent. <i>Journal of Organic Chemistry</i> , 2008, 73, 6657-6665.	3.2	17
78	Acetylcholinesterase Inhibitors as Disease-Modifying Therapies for Alzheimers Disease. <i>Current Medicinal Chemistry</i> , 2008, 15, 2433-2455.	2.4	238
79	Enantiodivergent synthesis of 3-amino-4,4-dimethyl-1-phenylpyrrolidin-2-one and derivatives: amino analogues of pantolactone. <i>Tetrahedron: Asymmetry</i> , 2007, 18, 2947-2958.	1.8	7
80	Highly Diastereoselective One-Pot Synthesis of Spiro{cyclopenta[a]indene-2,2'-indene}diones from 1-Indanones and Aromatic Aldehydes. <i>Journal of Organic Chemistry</i> , 2006, 71, 3464-3471.	3.2	19
81	Binding of 13-Amidohuprines to Acetylcholinesterase: Exploring the Ligand-Induced Conformational Change of the Gly117-Gly118 Peptide Bond in the Oxyanion Hole. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6833-6840.	6.4	19
82	Acetylcholinesterase triggers the aggregation of PrP 106-126. <i>Biochemical and Biophysical Research Communications</i> , 2006, 346, 89-94.	2.1	24
83	Effect of Acetylcholinesterase Inhibitors on AChE-Induced PrP106-126 Aggregation. <i>Journal of Molecular Neuroscience</i> , 2006, 30, 89-90.	2.3	6
84	Dimeric and Hybrid Anti-Alzheimer Drug Candidates. <i>Current Medicinal Chemistry</i> , 2006, 13, 399-422.	2.4	104
85	Editorial [Hot Topic: Alzheimer Drug Design Based on the Amyloid Hypothesis (Executive Editors: D.) Tj ETQq1 1 0.784314 rgBT /Over 1.9	1.9	2
86	A synthesis of levetiracetam based on (S)-N-phenylpantolactam as a chiral auxiliary. <i>Tetrahedron: Asymmetry</i> , 2005, 16, 3739-3745.	1.8	40
87	Nicotinic-receptor potentiator drugs, huprine X and galantamine, increase ACh release by blocking AChE activity but not acting on nicotinic receptors. <i>Brain Research</i> , 2005, 1061, 73-79.	2.2	6
88	Synthesis and Applications of (R)- and (S)-Pantolactone as Chiral Auxiliaries. <i>ChemInform</i> , 2005, 36, no.	0.0	0
89	(\pm)-huprine Y, (-)-huperzine A and tacrine do not show neuroprotective properties in an apoptotic model of neuronal cytoskeletal alteration. <i>Journal of Alzheimer's Disease</i> , 2005, 6, 577-583.	2.6	10
90	Synthesis and Pharmacological Evaluation of Huprine-Tacrine Heterodimers: Subnanomolar Dual Binding Site Acetylcholinesterase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 1701-1704.	6.4	68

#	ARTICLE	IF	CITATIONS
91	Effects of (±)-huprine Y and (±)-huprine Z, two new anticholinesterasic drugs, on muscarinic receptors. <i>Neuroscience Letters</i> , 2005, 379, 106-109.	2.1	8
92	Stereoselective synthesis of both enantiomers of N-Boc-1-aryl-3-aminobutyric acids. <i>Tetrahedron: Asymmetry</i> , 2004, 15, 311-321.	1.8	17
93	Synthesis of both enantiomers of baclofen using (R)- and (S)-N-phenylpantolactam as chiral auxiliaries. <i>Tetrahedron: Asymmetry</i> , 2004, 15, 2039-2044.	1.8	43
94	Synthesis of 13-acylamino-huprines: different behavior of diastereomeric 13-methanesulfonamido-huprines on PPA-mediated hydrolysis. <i>Tetrahedron</i> , 2004, 60, 5423-5431.	1.9	5
95	Synthesis of 13-acylamino-huprines: different behavior of diastereomeric 13-methanesulfonamido-huprines on PPA-mediated hydrolysis. <i>Tetrahedron</i> , 2004, 60, 5423-5423.	1.9	1
96	Synthesis and Applications of (R)- and (S)-Pantolactone as Chiral Auxiliaries. <i>Current Organic Chemistry</i> , 2004, 8, 1339-1380.	1.6	27
97	One-Pot Synthesis of N-Substituted Pantolactams from Pantolactone.. <i>ChemInform</i> , 2003, 34, no.	0.0	0
98	One-pot synthesis of N-substituted pantolactams from pantolactone. <i>Tetrahedron</i> , 2003, 59, 1971-1979.	1.9	15
99	Synthesis of diastereomeric 13-amido-substituted huprines as potential high affinity acetylcholinesterase inhibitors. <i>Tetrahedron</i> , 2003, 59, 4143-4151.	1.9	16
100	Neuroprotective effects of (±)-huprine Y on in vitro and in vivo models of excitotoxicity damage. <i>Experimental Neurology</i> , 2003, 180, 123-130.	4.1	23
101	Characterisation of the anticholinesterase activity of two new tacrine-huperzine A hybrids. <i>Neuropharmacology</i> , 2003, 44, 749-755.	4.1	38
102	Cholinergic Drugs in Pharmacotherapy of Alzheimers Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2002, 2, 11-25.	2.4	46
103	3D Structure of <i>Torpedo californica</i> Acetylcholinesterase Complexed with Huprine X at 2.1 Å... Resolution: Kinetic and Molecular Dynamic Correlates. <i>Biochemistry</i> , 2002, 41, 2970-2981.	2.5	126
104	EASY ACCESS TO 4-SUBSTITUTED (±)-HUPERZINE A ANALOGUES. <i>Synthetic Communications</i> , 2001, 31, 3507-3516.	2.1	7
105	Synthesis, in Vitro Pharmacology, and Molecular Modeling of syn-Huprines as Acetylcholinesterase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2001, 44, 4733-4736.	6.4	45
106	On the regioselectivity of the Friedländer reaction leading to huprines: stereospecific acid-promoted isomerization of syn-huprines to their anti-regioisomers. <i>Tetrahedron: Asymmetry</i> , 2001, 12, 2909-2914.	1.8	12
107	The pharmacology of novel acetylcholinesterase inhibitors, (±)-huprines Y and X, on the Torpedo electric organ. <i>European Journal of Pharmacology</i> , 2001, 421, 77-84.	3.5	10
108	New Syntheses of rac-Huperzine A and its rac-7-Ethyl-Derivative. Evaluation of Several Huperzine A Analogues as Acetylcholinesterase Inhibitors. <i>Tetrahedron</i> , 2000, 56, 4541-4553.	1.9	19

#	ARTICLE	IF	CITATIONS
109	Synthesis of Polysubstituted Bicyclo[3.3.1]nonane-3,7-diones from Cyclohexa-2,5-dienones and Dimethyl 1,3-Acetonedicarboxylate. <i>Tetrahedron</i> , 2000, 56, 8141-8151.	1.9	26
110	New Tacrine-Huperzine A Hybrids (Huprines): Highly Potent Tight-Binding Acetylcholinesterase Inhibitors of Interest for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2000, 43, 4657-4666.	6.4	185
111	Synthesis of an 11-unsubstituted analogue of (±)-huperzine A. <i>Tetrahedron</i> , 1999, 55, 8481-8496.	1.9	12
112	Synthesis, in Vitro Pharmacology, and Molecular Modeling of Very Potent Tacrine-Huperzine A Hybrids as Acetylcholinesterase Inhibitors of Potential Interest for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 3227-3242.	6.4	101
113	Synthesis of a Key Building Block for a Butyrolactone + 1,3-Diol Approach to the Polyol Part of Roflomycoin. <i>European Journal of Organic Chemistry</i> , 1998, 1998, 1031-1043.	2.4	8
114	Enantioselective synthesis of tacrine-huperzine A hybrids. Preparative chiral MPLC separation of their racemic mixtures and absolute configuration assignments by X-ray diffraction analysis. <i>Tetrahedron: Asymmetry</i> , 1998, 9, 835-849.	1.8	40
115	Synthesis and evaluation of tacrine-huperzine a hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 1998, 6, 427-440.	3.0	80
116	On the Synthesis of 2-Amino-4,6-difluorobenzonitrile: Highly Selective Formation of 5-Fluoro-3-nitro-1,2-benzoquinone 2-Diazide in the Attempted Sandmeyer Cyanation of 2,4-Difluoro-6-nitrobenzenediazonium Cation. <i>Journal of Chemical Research Synopses</i> , 1998, , 144-145.	0.3	3
117	Easy synthesis of 7-alkylbicyclo[3.3.1]non-6-en-3-ones by silica gel-promoted fragmentation of 3-alkyl-2-oxadamant-1-yl mesylates. <i>Tetrahedron</i> , 1996, 52, 5867-5880.	1.9	22
118	Synthesis of bridgehead polycyclic 1,2-diamines and 2-amino alcohol derivatives as Rigid acetylcholine analogs. <i>Liebigs Annalen</i> , 1995, 1995, 523-535.	0.8	5
119	Stereoselective deuteration of a bridgehead polycyclic 2-nitro alcohol through a retro-Henry reaction. <i>Tetrahedron</i> , 1995, 51, 6587-6590.	1.9	5
120	Unusual oxidation of bridgehead polycyclic 1,2-diamines and 2-aminoalcohols with dimethyldioxirane: Formation of dioximes and monooximes by cleavage of the central carbon-carbon bond. <i>Tetrahedron Letters</i> , 1995, 36, 1917-1920.	1.4	12
121	Alternative syntheses of bridgehead polycyclic 1,2-diamines and 2-aminoalcohols from di- and mono-oximes of some bicyclic diketones: Highly improved synthesis of tricyclo[3.3.1.0 ^{3,7}]nonane-3,7-diamine. <i>Tetrahedron Letters</i> , 1994, 35, 3187-3190.	1.4	14
122	Synthesis and evaluation of tacrine-related compounds for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 1994, 29, 205-221.	5.5	28